Brian Tanquelet
👤 SpeakerAppearances Over Time
Podcast Appearances
The company has been moving away from copycat versions of weight loss medications that help fuel its growth, instead prioritizing partnerships with brand name products.
Brian Tanquelet is research analyst at Jefferies.
Revenue came in at $608 million.
That was below the average analyst's estimate of $617.5 million.
In New York, Charlie Pellett, Bloomberg Radio.
The company has been moving away from copycat versions of weight loss medications that help fuel its growth, instead prioritizing partnerships with brand name products.
Brian Tanquelet is research analyst at Jefferies.
Revenue came in at $608 million.
That was below the average analyst's estimate of $617.5 million.
In New York, Charlie Pellett, Bloomberg Radio.
You certainly ask interesting questions.
What happened was that earlier this year, HIMSS signed an agreement with Novo Nordisk to basically say we're going to stop compounding or making our own versions of GLPs.
and we're just going to distribute a Novo Nordisk brand.